publication date: Dec. 4, 2020
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP
If you're not a subscriber why not join today?
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.
NCI is using a hub-and-spoke structure to engineer an ambitious data federation for pediatric cancers—which, if done right, is anticipated to become the gold standard for a new generation of comprehensive cancer databases.
NCI has joined a nationwide initiative to increase the number of underrepresented minority faculty at NIH-funded cancer hospitals.
On the way out, the Trump administration has finalized a rule that uses international reference prices to lower Medicare Part B prices.
- GRAIL and UK government plan to make Galleri multi-cancer early detection blood test available
- Raymond Bergan named deputy director at Fred & Pamela Buffett Cancer Center
- Ramsay Camp named chief of surgical oncology at Baylor College of Medicine
- IU’s Harikrishna Nakshatri receives $1.3 million to improve breast cancer treatment for Black women
- FDA and AACR collaborate on Project Livin’ Label
- Ohio State creates Clara D. Bloomfield Center for leukemia outcomes research
During my 30-year career in health care, I’ve worked with hundreds of community oncology practices. Most oncologists I’ve worked with have, for quite some time, intuitively understood that social determinants of health (SDOH) can significantly impact patient outcomes.
- UVA researchers identify gene responsible for metastasis of TNBC
- City of Hope initiates phase I study to test its first SARS-CoV-2 investigational vaccine
- Danyelza receives FDA approval for treatment of neuroblastoma
- Gavreto receives FDA approval for RET-altered thyroid cancers
- FDA approves first PSMA-targeted PET imaging drug for in prostate cancer
- European Commission approves Opdivo as second-line treatment for unresectable advanced, recurrent or metastatic ESCC
- EMA validates tepotinib application for treatment of advanced NSCLC with METex14 skipping alterations
The National Cancer Institute approved the following clinical research studies last month.